Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 274

1.

Risk of post-operative, pre-radiotherapy contralateral neck recurrence in patients treated with surgery followed by adjuvant radiotherapy for human papilloma virus-associated tonsil cancer.

Gershowitz J, Chao HH, Doucette A, Lukens JN, Swisher-McClure S, Weinstein GS, O'Malley BW Jr, Chalian AA, Rassekh CH, Newman JG, Cohen RB, Bauml JM, Aggarwal C, Lin A.

Br J Radiol. 2019 Oct 15:20190466. doi: 10.1259/bjr.20190466. [Epub ahead of print]

PMID:
31600090
2.

Immunotherapy for head and neck cancer: where are we now and where are we going?

Bauml JM, Aggarwal C, Cohen RB.

Ann Transl Med. 2019 Jul;7(Suppl 3):S75. doi: 10.21037/atm.2019.03.58. No abstract available.

3.

Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer.

Bange E, Marmarelis ME, Hwang WT, Yang YX, Thompson JC, Rosenbaum J, Bauml JM, Ciunci C, Alley EW, Cohen RB, Langer CJ, Carpenter E, Aggarwal C.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00326. Epub 2019 May 10.

4.

The impact of treatment package time on locoregional control for HPV+ oropharyngeal squamous cell carcinoma treated with surgery and postoperative (chemo)radiation.

Chao HH, Schonewolf CA, Tan EX, Swisher-McClure S, Ghiam AF, Weinstein GS, O'Malley BW Jr, Chalian AA, Rassekh CH, Newman JG, Cohen RB, Bauml JM, Aggarwal C, Lin A, Lukens JN.

Head Neck. 2019 Nov;41(11):3858-3868. doi: 10.1002/hed.25914. Epub 2019 Aug 14.

PMID:
31411356
5.

Treatment and Outcomes of Oropharyngeal Cancer in People with Human Immunodeficiency Virus.

Brickman CE, Propert KJ, Merlin JS, Liu JC, Eady S, Mcghee-Jez A, Ragin C, Grover S, Cohen RB, Gross R.

AIDS Res Hum Retroviruses. 2019 Oct;35(10):934-940. doi: 10.1089/AID.2019.0009. Epub 2019 Aug 29.

PMID:
31347379
6.

Lung Cancer-Related Mortality With Inhaled Insulin or a Comparator: Follow-Up Study of patients previously enrolled in Exubera Controlled Clinical Trials (FUSE) Final Results.

Gatto NM, Koralek DO, Bracken MB, Duggan WT, Lem J, Klioze S, Koch GG, Wise RA, Cohen RB, Jackson NC.

Diabetes Care. 2019 Sep;42(9):1708-1715. doi: 10.2337/dc18-2529. Epub 2019 Jul 22.

PMID:
31331907
7.

What if Acupuncture Were Covered by Insurance for Pain Management? A Cross-Sectional Study of Cancer Patients at One Academic Center and 11 Community Hospitals.

Liou KT, Hung TKW, Meghani SH, Epstein AS, Li QS, Romero SAD, Cohen RB, Mao JJ.

Pain Med. 2019 Apr 24. pii: pnz087. doi: 10.1093/pm/pnz087. [Epub ahead of print]

PMID:
31329938
8.

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.

Bauml JM, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T, Deshpande C, Miller L, Patel P, Alley E, Knepley C, Mutale F, Cohen RB, Langer CJ.

JAMA Oncol. 2019 Jul 11. doi: 10.1001/jamaoncol.2019.1449. [Epub ahead of print]

PMID:
31294762
9.

Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.

Bagley SJ, Talento S, Mitra N, Meropol NJ, Cohen RB, Langer CJ, Vachani A.

J Natl Compr Canc Netw. 2019 May 1;17(5):469-477. doi: 10.6004/jnccn.2018.7102.

10.

Targeting HER2/neu Oncogene Overexpression With Ado-Trastuzumab Emtansine in the Treatment of Metastatic Salivary Gland Neoplasms: A Single-Institution Experience.

Swed BL, Cohen RB, Aggarwal C.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00351. Epub 2019 Feb 15. No abstract available.

11.

First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.

He AR, Cohen RB, Denlinger CS, Sama A, Birnbaum A, Hwang J, Sato T, Lewis N, Mynderse M, Niland M, Giles J, Wallin J, Moser B, Zhang W, Walgren R, Plimack ER.

Oncologist. 2019 Sep;24(9):e930-e942. doi: 10.1634/theoncologist.2018-0411. Epub 2019 Mar 4.

PMID:
30833489
12.

Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.

Aggarwal C, Davis CW, Mick R, Thompson JC, Ahmed S, Jeffries S, Bagley S, Gabriel P, Evans TL, Bauml JM, Ciunci C, Alley E, Morrissette JJD, Cohen RB, Carpenter EL, Langer CJ.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00107. Epub 2018 Aug 31.

13.

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.

Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK.

J Clin Oncol. 2019 Feb 1;37(4):318-327. doi: 10.1200/JCO.2018.78.2276. Epub 2018 Dec 13.

PMID:
30557521
14.

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.

André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E.

Cell. 2018 Dec 13;175(7):1731-1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29. Review.

15.

Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data.

Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Di Stefano J, Knepley C, Limaye S, Mamtani R, Wisnivesky J, Damjanov N, Langer CJ, Cohen RB, Sigel K.

Cancer. 2019 Feb 1;125(3):406-415. doi: 10.1002/cncr.31816. Epub 2018 Oct 20.

PMID:
30341983
16.

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.

Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, Chien AL, Evans TL, Bauml JM, Alley EW, Ciunci CA, Berman AT, Cohen RB, Lieberman DB, Majmundar KS, Savitch SL, Morrissette JJD, Hwang WT, Elenitoba-Johnson KSJ, Langer CJ, Carpenter EL.

JAMA Oncol. 2019 Feb 1;5(2):173-180. doi: 10.1001/jamaoncol.2018.4305.

17.

Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.

Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Knoblock DM, Bauml JM, Weinstein GS, Lin A, Boyer J, Sakata L, Tan S, Anton A, Dickerson K, Mangrolia D, Vang R, Dallas M, Oyola S, Duff S, Esser M, Kumar R, Weiner D, Csiki I, Bagarazzi ML.

Clin Cancer Res. 2019 Jan 1;25(1):110-124. doi: 10.1158/1078-0432.CCR-18-1763. Epub 2018 Sep 21.

PMID:
30242022
18.

Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.

Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Limaye S, Damjanov N, Di Stefano J, Ciunci C, Genden EM, Wisnivesky JP, Ferrandino R, Mamtani R, Langer CJ, Cohen RB, Sigel K.

J Natl Cancer Inst. 2019 May 1;111(5):490-497. doi: 10.1093/jnci/djy133.

19.

Barriers to physical activity: a study of academic and community cancer survivors with pain.

Romero SAD, Brown JC, Bauml JM, Hay JL, Li QS, Cohen RB, Mao JJ.

J Cancer Surviv. 2018 Dec;12(6):744-752. doi: 10.1007/s11764-018-0711-y. Epub 2018 Sep 4.

PMID:
30182150
20.

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.

Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A.

Invest New Drugs. 2019 Feb;37(1):87-97. doi: 10.1007/s10637-018-0610-0. Epub 2018 May 21.

21.

Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.

Smit EF, Garon EB, Reck M, Cappuzzo F, Bidoli P, Cohen RB, Gao L, O'Brien LM, Lee P, Zimmermann A, Ferry DR, Melemed AS, Pérol M.

Cancer Chemother Pharmacol. 2018 Jul;82(1):77-86. doi: 10.1007/s00280-018-3560-5. Epub 2018 May 2.

PMID:
29721850
22.

The association between fatigue and pain symptoms and decreased physical activity after cancer.

Romero SAD, Jones L, Bauml JM, Li QS, Cohen RB, Mao JJ.

Support Care Cancer. 2018 Oct;26(10):3423-3430. doi: 10.1007/s00520-018-4203-4. Epub 2018 Apr 19.

23.

Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.

Aggarwal C, Haas AR, Metzger S, Aguilar LK, Aguilar-Cordova E, Manzanera AG, Gómez-Hernández G, Katz SI, Alley EW, Evans TL, Bauml JM, Cohen RB, Langer CJ, Albelda SM, Sterman DH.

Mol Ther. 2018 May 2;26(5):1198-1205. doi: 10.1016/j.ymthe.2018.02.015. Epub 2018 Feb 21.

24.

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.

Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Damian S, Hong RL, Le Tourneau C, Day D, Varga A, Elez E, Wallmark J, Saraf S, Thanigaimani P, Cheng J, Keam B.

Am J Clin Oncol. 2018 Feb 21. doi: 10.1097/COC.0000000000000429. [Epub ahead of print]

25.

Effect of Prophylactic Cranial Irradiation on Overall Survival in Metastatic Small-Cell Lung Cancer: A Propensity Score-Matched Analysis.

Sharma S, McMillan MT, Doucette A, Cohen RB, Berman A, Levin W, Simone CB 2nd, Shabason J.

Clin Lung Cancer. 2018 May;19(3):260-269.e3. doi: 10.1016/j.cllc.2017.12.003. Epub 2017 Dec 14.

26.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.

O'Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, Ejadi S, Piha-Paul SA, Stein MN, Abdul Razak AR, Dotti K, Santoro A, Cohen RB, Gould M, Saraf S, Stein K, Han SW.

PLoS One. 2017 Dec 28;12(12):e0189848. doi: 10.1371/journal.pone.0189848. eCollection 2017.

27.

Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.

Aggarwal C, Wang X, Ranganathan A, Torigian D, Troxel A, Evans T, Cohen RB, Vaidya B, Rao C, Connelly M, Vachani A, Langer C, Albelda S.

Lung Cancer. 2017 Oct;112:118-125. doi: 10.1016/j.lungcan.2017.08.008. Epub 2017 Aug 12.

PMID:
29191584
28.

The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer.

Kesarwala AH, Lu DJ, Xanthopoulos E, Apisarnthanarax S, Cengel KA, Evans TL, Aggarwal C, Cohen RB, Langer CJ, Rengan R, Simone CB 2nd.

Clin Lung Cancer. 2018 Mar;19(2):e205-e209. doi: 10.1016/j.cllc.2017.10.001. Epub 2017 Oct 12.

29.

Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II Study.

Aggarwal C, Cohen RB, Yu E, Hwang WT, Bauml JM, Alley E, Evans TL, Langer CJ.

Clin Lung Cancer. 2018 Mar;19(2):157-162. doi: 10.1016/j.cllc.2017.10.007. Epub 2017 Oct 19.

PMID:
29129435
30.

Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer.

Marmarelis M, Thompson JC, Aggarwal C, Evans TL, Carpenter E, Cohen RB, Langer CJ, Bauml J.

Ann Transl Med. 2017 Sep;5(18):380. doi: 10.21037/atm.2017.07.29. Review.

31.

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.

Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, Thanigaimani P, Cheng JD, Hansen AR.

J Clin Oncol. 2017 Dec 20;35(36):4050-4056. doi: 10.1200/JCO.2017.73.3675. Epub 2017 Aug 24.

PMID:
28837405
32.

Delayed osteomyelitis resulting from an extension injury of the cervical spine: case report.

Palmer V, Cohen RB, Braffman B, Brockmeyer DL, Spader HS.

J Neurosurg Pediatr. 2017 Oct;20(4):388-392. doi: 10.3171/2017.5.PEDS1777. Epub 2017 Aug 11.

PMID:
28799857
33.

The Influence of Lordotic cages on creating Sagittal Balance in the CMIS treatment of Adult Spinal Deformity.

Anand N, Cohen RB, Cohen J, Kahndehroo B, Kahwaty S, Baron E.

Int J Spine Surg. 2017 Jun 30;11:23. doi: 10.14444/4023. eCollection 2017.

34.

Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.

Rwigema JM, Verma V, Lin L, Berman AT, Levin WP, Evans TL, Aggarwal C, Rengan R, Langer C, Cohen RB, Simone CB 2nd.

Cancer. 2017 Nov 1;123(21):4244-4251. doi: 10.1002/cncr.30870. Epub 2017 Jul 5.

35.

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.

Infante JR, Cohen RB, Kim KB, Burris HA 3rd, Curt G, Emeribe U, Clemett D, Tomkinson HK, LoRusso PM.

Invest New Drugs. 2017 Oct;35(5):669. doi: 10.1007/s10637-017-0479-3. No abstract available.

36.

Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors.

Patel SH, Rimner A, Cohen RB.

Transl Lung Cancer Res. 2017 Apr;6(2):186-195. doi: 10.21037/tlcr.2017.03.04. Review.

37.

Beyond Positive Margins and Extracapsular Extension: Evaluating the Utilization and Clinical Impact of Postoperative Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer.

Trifiletti DM, Smith A, Mitra N, Grover S, Lukens JN, Cohen RB, Read P, Mendenhall WM, Lin A, Swisher-McClure S.

J Clin Oncol. 2017 May 10;35(14):1550-1560. doi: 10.1200/JCO.2016.68.2336. Epub 2017 Feb 13.

PMID:
28475848
38.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.

Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J.

Ann Oncol. 2017 May 1;28(5):1036-1041. doi: 10.1093/annonc/mdx029.

39.

Comparison of a Newer Versus Older Protocol for Circumferential Minimally Invasive Surgical (CMIS) Correction of Adult Spinal Deformity (ASD)-Evolution Over a 10-Year Experience.

Anand N, Cohen JE, Cohen RB, Khandehroo B, Kahwaty S, Baron E.

Spine Deform. 2017 May;5(3):213-223. doi: 10.1016/j.jspd.2016.12.005.

PMID:
28449965
40.

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.

Infante JR, Cohen RB, Kim KB, Burris HA 3rd, Curt G, Emeribe U, Clemett D, Tomkinson HK, LoRusso PM.

Invest New Drugs. 2017 Oct;35(5):576-588. doi: 10.1007/s10637-017-0459-7. Epub 2017 Apr 19. Erratum in: Invest New Drugs. 2017 Jul 5;:.

41.

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.

Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ.

Lung Cancer. 2017 Apr;106:1-7. doi: 10.1016/j.lungcan.2017.01.013. Epub 2017 Jan 25.

PMID:
28285682
42.

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.

LoRusso PM, Infante JR, Kim KB, Burris HA 3rd, Curt G, Emeribe U, Clemett D, Tomkinson HK, Cohen RB.

BMC Cancer. 2017 Mar 6;17(1):173. doi: 10.1186/s12885-017-3143-6.

43.

Unsupervised exercise in survivors of human papillomavirus related head and neck cancer: how many can go it alone?

Bauml J, Kim J, Zhang X, Aggarwal C, Cohen RB, Schmitz K.

J Cancer Surviv. 2017 Aug;11(4):462-468. doi: 10.1007/s11764-017-0604-5. Epub 2017 Feb 13.

PMID:
28194641
44.

Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.

Infante JR, Patnaik A, Verschraegen CF, Olszanski AJ, Shaheen M, Burris HA, Tolcher AW, Papadopoulos KP, Beeram M, Hynes SM, Leohr J, Lin AB, Li LQ, McGlothlin A, Farrington DL, Westin EH, Cohen RB.

Cancer Chemother Pharmacol. 2017 Feb;79(2):315-326. doi: 10.1007/s00280-016-3205-5. Epub 2017 Jan 17.

PMID:
28097385
45.

Transoral Robotic Surgery-Assisted Endoscopy With Primary Site Detection and Treatment in Occult Mucosal Primaries.

Hatten KM, O'Malley BW Jr, Bur AM, Patel MR, Rassekh CH, Newman JG, Cannady SB, Chalian AA, Hodnett BL, Lin A, Lukens JN, Cohen RB, Bauml JM, Montone KT, Livolsi VA, Weinstein GS.

JAMA Otolaryngol Head Neck Surg. 2017 Mar 1;143(3):267-273. doi: 10.1001/jamaoto.2016.3419.

PMID:
27930761
46.

Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non-Small-cell Lung Cancer.

Bagley SJ, Vitale S, Zhang S, Aggarwal C, Evans TL, Alley EW, Cohen RB, Langer CJ, Blair IA, Vachani A, Whitehead AS.

Clin Lung Cancer. 2017 Mar;18(2):e143-e149. doi: 10.1016/j.cllc.2016.10.010. Epub 2016 Oct 26.

47.

Risk of lymph node metastasis and recommendations for elective nodal treatment in squamous cell carcinoma of the nasal cavity and maxillary sinus: a SEER analysis.

Ahn PH, Mitra N, Alonso-Basanta M, Palmer JN, Adappa ND, O'Malley BW Jr, Rassekh C, Chalian A, Cohen RB, Lin A.

Acta Oncol. 2016 Sep - Oct;55(9-10):1107-1114. doi: 10.1080/0284186X.2016.1216656. Epub 2016 Aug 11.

PMID:
27685421
48.

A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J.

Cancer. 2016 Dec 1;122(23):3641-3649. doi: 10.1002/cncr.30317. Epub 2016 Sep 20.

49.

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.

Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, Aggarwal C, Kosteva JA, Alley E, Ciunci C, Cohen RB, Bagley S, Stonehouse-Lee S, Sherry VE, Gilbert E, Langer C, Vachani A, Carpenter EL.

Clin Cancer Res. 2016 Dec 1;22(23):5772-5782. Epub 2016 Sep 6.

50.

Scan-associated distress in lung cancer: Quantifying the impact of "scanxiety".

Bauml JM, Troxel A, Epperson CN, Cohen RB, Schmitz K, Stricker C, Shulman LN, Bradbury A, Mao JJ, Langer CJ.

Lung Cancer. 2016 Oct;100:110-113. doi: 10.1016/j.lungcan.2016.08.002. Epub 2016 Aug 16.

Supplemental Content

Loading ...
Support Center